These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23999236)

  • 1. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
    Wartlick F; Bopp A; Henninger C; Fritz G
    Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
    Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
    J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
    Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
    Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
    Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
    Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.
    Siu WY; Lau A; Arooz T; Chow JP; Ho HT; Poon RY
    Mol Cancer Ther; 2004 May; 3(5):621-32. PubMed ID: 15141020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
    Drummond CJ; Finlay GJ; Broome L; Marshall ES; Richardson E; Baguley BC
    Invest New Drugs; 2011 Oct; 29(5):1102-10. PubMed ID: 20567995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenolic-containing organic extracts of mulberry (Morus alba L.) leaves inhibit HepG2 hepatoma cells through G2/M phase arrest, induction of apoptosis, and inhibition of topoisomerase IIα activity.
    Naowaratwattana W; De-Eknamkul W; De Mejia EG
    J Med Food; 2010 Oct; 13(5):1045-56. PubMed ID: 20828312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
    Kitdumrongthum S; Reabroi S; Suksen K; Tuchinda P; Munyoo B; Mahalapbutr P; Rungrotmongkol T; Ounjai P; Chairoungdua A
    Biomed Pharmacother; 2020 Jul; 127():110149. PubMed ID: 32344256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
    Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
    Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
    Bau JT; Kang Z; Austin CA; Kurz EU
    Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of prostate smooth muscle contraction and prostate stromal cell growth by the inhibitors of Rac, NSC23766 and EHT1864.
    Wang Y; Kunit T; Ciotkowska A; Rutz B; Schreiber A; Strittmatter F; Waidelich R; Liu C; Stief CG; Gratzke C; Hennenberg M
    Br J Pharmacol; 2015 Jun; 172(11):2905-17. PubMed ID: 25631101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
    Kurose A; Tanaka T; Huang X; Halicka HD; Traganos F; Dai W; Darzynkiewicz Z
    Cytometry A; 2005 Nov; 68(1):1-9. PubMed ID: 16184611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
    Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
    J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
    Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
    PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
    Guo L; Liu X; Nishikawa K; Plunkett W
    Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses.
    Fan JR; Huang TH; Wen CY; Shen TL; Li TK
    Eur J Pharmacol; 2010 Jul; 638(1-3):13-20. PubMed ID: 20406630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.
    Ma J; Wang Y; Zheng D; Wei M; Xu H; Peng T
    Cardiovasc Res; 2013 Jan; 97(1):77-87. PubMed ID: 23027656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.